Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

Article Type

Case Report

Published

The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.

Read more

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Article Type

Case Report

Published

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.

Read more

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

María del Carmen Pingarrón Santofimia MD, Silvia Pilar González Rodríguez MD, PhD, Mariella Lilue MD, Santiago Palacios MD, PhD

Article Type

Case Report

Published

In this case report, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopenia– osteoporosis are examined in postmenopausal women during treatment with ospemifene for vulvar and vaginal atrophy (VVA), a component of the genitourinary syndrome of menopause.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.